3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Lymphoma
14
Leukemia
14
Breast Neoplasms
9
Lymphoma, Large B-Cell, Diffuse
7
Osteosarcoma
5
Gestational Trophoblastic Disease
4
Central Nervous System Neoplasms
4
Meningeal Carcinomatosis
3
Lymphoma, Extranodal NK-T-Cell
3
Astrocytoma
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Oligodendroglioma
2
Myelodysplastic Syndromes
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Leukemia, T-Cell
2
Leukemia, Myeloid, Acute
2
Leukemia, Biphenotypic, Acute
2
Hodgkin Disease
2
Graft vs Host Disease
2
Drug-Related Side Effects and Adverse Reactions
2
Dendritic Cell Sarcoma, Interdigitating
2
Choroid Plexus Neoplasms
2
Burkitt Lymphoma
2
Water Intoxication
1
Thrombocythemia, Essential
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Spinal Cord Neoplasms
1
Interventions
paclitaxel-Angiopep-2 conjugate
1
eribulin
1
Methotrexate
1
Capecitabine
1
Amplified Fragment Length Polymorphism Analysis
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Meningeal Neoplasms
×
Methotrexate
×
Clear all
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled